Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients
June 04, 2021 09:00 ET
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...
Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments
May 14, 2020 08:00 ET
|
Cellworks Group, Inc.
SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced...